Activation of D1 and D2 dopamine receptors increases the activity of the somatostatin receptor-effector system in the rat frontoparietal cortex by Izquierdo Claros, Rosa María et al.
Activation of D1 and D2 Dopamine
Receptors Increases the Activity of the
Somatostatin Receptor-Effector System in
the Rat Frontoparietal Cortex
Rosa M. Izquierdo-Claros, Marı´a del Carmen Boyano-Ada´nez, and
Eduardo Arilla-Ferreiro*
Departamento de Bioquı´mica y Biologı´a Molecular, Facultad de Medicina, Universidad de Alcala´,
Alcala´ de Henares, Madrid, Spain
The role of dopamine D1 and D2 receptor subtypes in the
regulation, in vivo, of the somatostatin (SRIF) receptor-
effector system in rat frontoparietal cortex was investi-
gated. The D1-receptor agonist SKF 38393 (4 mg/kg) or
the D2-receptor agonist bromocriptine (2 mg/kg), admin-
istered intraperitoneally to rats, increased the number of
SRIF receptors without altering the affinity constant, an
effect antagonized by both SCH 23390 (0.25 mg/kg) and
raclopride (5 mg/kg), D1 and D2 receptor antagonists,
respectively. These antagonists alone had no effect on
[125I]Tyr3 octreotide binding to its receptors. No change
in binding was detected when the dopamine agonists
were added in vitro. Basal adenylyl cyclase (AC) activity
was increased by SKF 38393 treatment and decreased
by bromocriptine. Octreotide (SMS 201-995)-mediated
inhibition of basal and forskolin-stimulated AC was in-
creased by SKF 38393 or bromocriptine treatment. In
frontoparietal cortical slices, basal inositol-1,4,5-
triphosphate (IP3) levels were decreased by bromocrip-
tine treatment but were unaffected by SKF 38393. SMS
201-995 increased the IP3 accumulation in control, SKF
38393-, and bromocriptine-treated rats. Insofar as SRIF
and dopamine appear to be involved in motor regulation
and could well modulate somatosensory functions in
frontal and parietal cortex, respectively, heterologous re-
ceptor regulation may have important repercussions re-
garding the control exerted by these neurotransmitters
on frontal and parietal cortical function in the intact
animal. J. Neurosci. Res. 62:91–98, 2000.
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Several studies have indicated selective localization
of somatostatin (SRIF)-like immunoreactivity in deep
cortical layers (Finley et al., 1981; Hendry et al., 1984;
Johansson et al., 1984). Cerebral cortical membranes con-
tain one of the largest SRIF receptor concentrations (Sri-
kant and Patel, 1981; Reubi and Maurer, 1985; Krantic et
al., 1990). The effects of SRIF on the central nervous
system (CNS) are mediated by G-protein-coupled recep-
tors (Law et al., 1991). Following the cloning of the genes
encoding for at least five SRIF receptor subtypes, labelled
SSTR1–5 (Hoyer et al., 1995), it became evident that the
SS1/SRIF-1 class comprises SSTR2, SSTR3, and SSTR5
receptors, whereas the SS2/SRIF-2 class consists of
SSTR1 and SSTR4 receptors (Brunns et al., 1995). All
these receptors mediate inhibition of adenylyl cyclase (AC)
activity (Patel, 1999) whereas SSTR2 and SSTR5 also
couple to phospholipase C (PLC) in CNS. The deeper
layers of cortical areas, rich in SRIF and its receptors, have
been shown to contain an innervation of dopamine (DA)-
positive nerve terminals originating from the ventral mid-
brain tegmentum (Descarries et al., 1987). The dopami-
nergic input to the frontal and parietal cortices plays an
important role in sensorimotor functions (Gaspar et al.,
1995), such as SRIF (Welker, 1971; Finley et al., 1981;
Epelbaum et al., 1982). DA exerts its action via dopamine
D1-like (D1 and D5) and D2-like (D2, D3, and D4)
receptors, although the neural circuits involved are not
completely understood (Civelli et al., 1993). Several stud-
ies suggest that SRIF and DA receptors are colocalized on
neuronal subgroups (Chneiweiss et al., 1985a). Behavioral
studies have shown the importance of an intact soma-
tostatinergic system in the full expression of DA-mediated
behaviors (Lee et al., 1988). Although interactions be-
tween SRIF and dopaminergic neurons are well docu-
mented (Pe´rez-Oso et al., 1989; Salin et al., 1990; Shog-
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monian and Chesselet, 1991; Engber et al., 1992; De los
Frailes et al., 1993; Pe´rez-Oso and Arilla, 1993;
Rodrı´guez-Sa´nchez et al., 1997), there are no reports
concerning the influence of D1 and D2 dopamine recep-
tors on the SRIF receptor-effector system located in the
cerebral cortex.
Because the deeper cortical layers are enriched in
SS1/SRIF1 receptor sites (Krantic et al., 1990) and the
stable SRIF octapeptide SMS 201-995 (octreotide) is se-
lective for the SS1/SRIF1 site (Krantic et al., 1992; Hoyer
et al., 1994), we have used octreotide and its tyrosine
analogue, code named SDZ 204-090, to study the effect
of SKF 38393, a D1-receptor agonist, and bromocriptine,
a D2-receptor agonist, on the specific binding of
[125I]Tyr3 octreotide to its receptors and on the ability of
SMS 201-995 to inhibit basal and forskolin (FK)-
stimulated AC activity in rat frontoparietal cortical mem-
branes. In addition, the effect of these compounds on SMS
201-995-stimulated inositol 1,4,5-triphosphate (IP3) accu-
mulation in the rat frontoparietal cortex was examinated.
The effects of pretreatment with the D1-receptor antag-
onist, SCH 23390, or the D2-receptor antagonist, raclo-
pride, on the above-cited parameters were also evaluated.
MATERIALS AND METHODS
Materials
The peptide SMS 201-995 and its tyrosine analogue SDZ
204-090 were kindly donated by Sandoz (Basel, Switzerland);
carrier-free Na125I (IMS 300; 100 mCi/ml) was purchased from
the Radiochemical Centre (Amersham, U.K.); SKF 38393 and
SCH 23390 were purchased from Research Biochemicals Inc.
(Natick, MA); raclopride was kindly donated by Astra Ifesa
(Barcelona, Spain); bromocriptine, bacitracin, BSA, forskolin,
phenylmethylsulphonyl fluoride, GTP, and 3-isobutyl-1-
methylxanthine were purchased from Sigma (St. Louis, MO);
IP3 and inositol-1,2,3,4,5,6-hexaphosphate (IP6) were from
Calbiochem (San Diego, CA); [3H]IP3 and [
3H]cAMP were
purchased from DuPont (Boston, MA). All other reagents were
of the highest purity commercially available.
Experimental Animals
All experimental procedures conform to the guidelines
established by the Animal Care and Use Committee of our
University and were accordingly approved prior to implemen-
tation. The animals used in this study were male Wistar rats with
an average weight of 200–250 g. Rats were maintained on a
12-hr light-dark cycle (lights on 07:00–19:00 hr) and allowed
free access to food. The rats were injected intraperitoneally (i.p.)
with 4 mg/kg of SKF 38393 dissolved in saline or 2 mg/kg of
bromocriptine dissolved in 0.5 ml ethanol 70%-0.14 M NaCl
(1:1.5 v/v). In other experimental groups, SCH 23390 (0.25 mg/
kg, i.p.) or raclopride (5 mg/kg, i.p.), dissolved in saline, was
administered 30 min before their corresponding agonist, SKF
38393 (4 mg/kg, i.p.) or bromocriptine (2 mg/kg, i.p.), re-
spectively. A third group of animals was injected i.p. with
0.25 mg/kg SCH 23390 or 5 mg/kg raclopride. Drug doses
were selected according to the effective doses reported in pre-
vious studies (Augood et al., 1991; Rodrı´guez-Sa´nchez et al.,
1997). Control animals selected for each group were injected
with equivalent volumes of the corresponding vehicle. Rats
were sacrificed by decapitation 3 hr after the last drug injection
(Engber et al., 1992). The brain was rapidly removed, and the
frontoparietal cortex was dissected over ice as previously out-
lined (Glowinski and Iversen, 1966).
Iodination of SDZ 204-090
The stable SRIF analogue SDZ 204-090, which has pre-
viously been demonstrated to bind specifically to SRIF receptors
with high affinity (Reubi, 1985), was radiodinated according to
a technique described for other SRIF-related peptides (Anto-
niotti et al., 1984). Briefly, 10 ml of a Na125I solution (1 mCi)
were added to 10 mg of SDZ 204-090 dissolved in 50 ml of a
0.25 M sodium phosphate buffer, pH 7.5. Subsequently, five
additions of 5 ml of chloramine-T (0.5 mg/ml in water) were
carried out, with 10 sec intervals between each addition. Finally,
120 ml of a tyrosine solution (2 mg/ml in phosphate buffer
0.5 M/NaOH 0.2 M) were added. The mixture was loaded
onto a Bondapak C18 column (30 3 0.39 cm i.d.), and, with a
Waters Associates liquid chromatograph, the tracer was eluted at
a flow of 1 ml/min in a preprogrammed nonlinear gradient
rising from 20% to 80% (v/v) acetonitrile in 0.25 M triethyl-
ammonium phosphate, pH 3.5, in 40 min. The tracer was eluted
after 15 min. Radioactivity in the fractions containing the tracer
was found to be 900 Ci/mmol.
Binding Assay
Rat frontoparietal cortical membranes were prepared as
previously described (Reubi, 1985). Membrane protein was
quantified by a technique previously described (Lowry et al.,
1951), using BSA as a standard. Specific SMS 201-995 binding
was measured according to a modified method (Czernik and
Petrack, 1983). Briefly, frontoparietal cortical membranes (0.036
mg protein/ml) were incubated in 250 ml of a medium con-
taining 50 mM Tris-HCl buffer, pH 7.5, 5 mM MgCl2, 0.2%
(w/v) BSA, and 0.1 mg/ml bacitracin, with 200 pM [125I]Tyr3
octreotide in either the absence or the presence of 0.01–100 nM
of SMS 201-995. After incubation for 90 min at 25°C, the free
radioligand was separated from the bound radioligand by cen-
trifugation at 11,000g for 2 min, and the resultant pellet was
counted for radioactivity in a Kontron g-counter. Nonspecific
binding was obtained from the amount of radioactivity bound in
the presence of 1027 M unlabelled SMS 201-995 and repre-
sented 20% of the binding observed in the absence of unlabelled
peptide. This nonspecific component was subtracted from the
total bound radioactivity to obtain the corresponding specific
binding.
Adenylyl Cyclase Assay
AC activity was measured as previously reported (Houslay
et al., 1976), with minor modifications. Briefly, fronto-
parietal cortical membranes (0.036 mg/ml) were incubated
with 1.5 mM ATP, 5 mM MgSO4, 10 mM GTP, an ATP-
regenerating system (7.5 mg/ml creatine phosphate and 1 mg/ml
creatine kinase), 1 mM 3-isobutyl-1-methylxanthine, 0.1 mM
phenylmethylsulphonyl fluoride, 1 mg/ml bacitracin, 1 mM
EDTA, and test substances (1025 M SMS 201-995 or 1025 M
FK) in 0.1 ml of 0.025 M triethanolamine/HCl buffer, pH 7.4.
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After a 15 min incubation at 30°C, the reaction was stopped by
heating the mixture for 3 min. After getting it cool, 0.2 ml of an
alumina slurry (0.75 g/ml in triethanolamine/HCl buffer, pH
7.4) were added, and the resulting suspension was centrifuged at
3,000g. The supernatant was removed to the cAMP assay as
previously described (Gilman, 1970).
IP3 Analyses
Cross-chopped frontoparietal cortical slices (250 3 250 mm)
were prepared from male Wistar rats (200–250 g) and preincu-
bated for 45 min at 37°C in Krebs bicarbonate buffer (118 mM
NaCl, 4.7 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 25 mM
NaHCO3, 11.7 mM glucose, 10 mM HEPES), pH 7.4, satu-
rated with O2/CO2 (95/5%), with buffer replacement and gas-
sing every 15 min (Challiss et al., 1988). Slices were allowed to
sediment, and 50 ml of packed slices were added to tubes
containing 200 ml of Krebs buffer and 20 ml of 1.5 mM LiCl.
The samples were gassed regularly, capped, and incubated. SMS
201-995 (1027 M) in a volume of 30 ml was subsequently added
to these tubes. Incubation was terminated by addition of 500 ml
of 0.5 M trichloroacetic acid (TCA). Acidified samples were left
on ice for 15 min and subsequently centrifuged for 15 min at
1,800g. To remove TCA, the supernatants were washed five
times with 1.25 ml of water-saturated diethyl ether, and, finally,
200 ml of 50 mM Tris-HCl, pH 8.4, were added. The protein
concentration in the tissue pellets was determined as previously
described (Lowry et al., 1951).
The specific binding of [3H]IP3 to a preparation of bovine
cerebellum membranes was used as a radioreceptor assay to
determine the IP3 concentration in these slices, according to the
method previously described (Bredt et al., 1989). Bovine cere-
bellar membranes were prepared by homogenizing bovine cer-
ebella in a cold buffer A (50 mM Tris-HCl, 1 mM EDTA and
1 mM 2-mercaptoethanol), pH 7.7, to obtain a protein concen-
tration of 4 mg/ml (Challiss et al., 1988). These membranes
(50 mg/tube) were added to Eppendorf tubes containing 25 ml
of [3H]IP3 (5 nCi/tube) and 50 ml of unknown or standard
samples containing IP3 (0.005 mM-5 mM in buffer A, pH 8.6)
or IP6 (1% w/v in buffer A, pH 8.6) to define nonspecific
binding. All tubes were incubated for 10 min at 4°C. Separation
of bound and free IP3 was achieved by centrifugation at 10,000g
for 5 min. After aspiration of the supernatant, 50 ml of 0.15 M
NaOH were added to each tube, and the pellet was dissolved by
shaking. The radioactivity was determined by liquid scintillation
spectrometry. The IP3 content was determined by interpolating
the inhibition of [3H]IP3 binding on a calibration curve with
known amounts of IP3. Nonspecific binding was 13% of the
total binding.
Data Analysis
The computer program LIGAND (Munson and Rod-
bard, 1980) was used to analyze the binding data. The use of this
program enabled us to select receptor models that best fit a given
set of binding data. The same program was also used to present
data in the form of Scatchard plots (Scatchard, 1949) and to
compute values for receptor affinity (Kd) and density (Bmax)
that best fit the sets of binding data for each rat. Statistical
comparisons of all the data were carried out by one-way analysis
of variance (ANOVA) and the Student’s Newman-Keuls test.
Means among groups were considered significantly different
when P values were ,0.05. Each experiment was performed in
duplicate.
RESULTS
Stoichiometric experiments were performed on rat
frontoparietal cortical membranes using a fixed concen-
tration of [125I]Tyr3 octreotide and increasing doses of
unlabelled SMS 201-995 at 25°C for 90 min. The com-
petition binding curves are shown in Figures 1 and 2. The
corresponding Scatchard analysis was linear and essentially
parallel (Figs. 1, 2, right panel). Interpretation of these data
with the LIGAND computer program (Munson and Rod-
bard, 1980) resulted in the best fit for a model with one
type of SRIF receptor. Frontoparietal cortical membranes
from SKF 38393- or bromocriptine-treated rats exhibited
significant increases in the maximum SRIF binding capac-
ity compared to controls. However, the corresponding Kd
values remained unchanged after treatment. Under speci-
fied conditions, the effect of the D1 agonist was similar to
that of the D2 agonist (Tables I, II). Pretreatment with
SCH 23390 or raclopride completely blocked the SKF
38393- or bromocriptine-induced changes in the number
of SMS 201-995 receptors, respectively (Figs. 1, 2, Tables
I, II). The administration of SCH 23390 or raclopride
alone did not produce any changes in the [125I]Tyr3 octreo-
tide binding in frontoparietal cortical membranes. The in
Fig. 1. Binding of [125I]Tyr3 octreotide to rat frontoparietal cortical
membranes. Left: Displacement of [125I]Tyr3 octreotide by increasing
concentrations of unlabelled SMS 201-995 to frontoparietal cortical
membranes. Specific binding was computed as described in Materials
and Methods. Membranes (0.036 mg protein/ml) were incubated for
90 min at 25°C in the presence of 200 pM [125I]Tyr3 octreotide and
increasing concentrations of SMS 201-995. Points correspond to values
for the animals in the control group pool (open circles; n 5 5), the SKF
38393 (4 mg/kg, i.p.)-treated group (solid circles; n 5 5), and the SCH
23390 (0.25 mg/kg, i.p.) plus SKF 38393 (4 mg/kg, i.p.)-treated group
(triangles; n 5 5). Each point is the mean of five separate experiments,
each performed in duplicate. In the control group, the data are values
of a pool of the control groups, because Bmax and Kd values of the
controls were not affected by the vehicle. Right: Scatchard analysis of
the binding data.
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vitro addition of SKF 38393 or bromocriptine to the
incubation medium at the time of the binding assay had no
effect on frontoparietal cortical SRIF receptors (data not
shown). The signaling pathways coupled to SRIF recep-
tors were evidenced by the ability of SMS 201-995 to
inhibit AC activity and to stimulate accumulation of IP3.
We examined the inhibitory effect of increasing concen-
trations of SMS 201-995 on basal and FK (1025 M)-
stimulated AC activity in frontoparietal cortical mem-
branes of control rats. The somatostatinergic inhibition of
both basal and FK-stimulated AC activity was significant
only for the maximal dose tested (1025 M; Fig. 3). Because
the SMS 201-995 concentration necessary to achieved
inhibition of AC activity was 1025 M, this concentration
was used in a subsequent detailed study of basal and
FK-stimulated AC activity in control rats and rats treated
with SKF 38393 or bromocriptine. The effect of SKF
38393 or bromocriptine on basal and FK-stimulated AC
activity was markedly increased or decreased, respectively,
in frontoparietal cortical membranes compared to controls
(Table III). In the SKF 38393 or bromocriptine groups,
the degree of SMS 201-995-mediated enzyme inhibition
of both basal and FK-stimulated AC activity was signifi-
cantly higher than in the control groups. This SMS 201-
Fig. 2. Binding of [125I]Tyr3 octreotide to rat frontoparietal cortical
membranes. Left: Displacement of [125I]Tyr3 octreotide by increasing
concentrations of unlabelled SMS 201-995 to frontoparietal cortical
membranes. Specific binding was computed as described in Materials
and Methods. Membranes (0.036 mg of protein/ml) were incubated for
90 min at 25°C in the presence of 200 pM [125I]Tyr3 octreotide and
increasing concentrations of SMS 201-995. Points correspond to values
for the animals in the control group pool (open circles; n 5 5), the
bromocriptine (2 mg/kg, i.p.)-treated group (solid circles; n 5 5) and
the raclopride (5 mg/kg, i.p.) plus bromocriptine (2 mg/kg, i.p.)-
treated group (triangles; n 5 5). Each point is the mean of five separate
experiments, each performed in duplicate. In the control group, the
data are values of a pool of the control groups, because Bmax and Kd
values of the controls were not affected by the vehicle. Right: Scat-
chard analysis of the binding data.
TABLE I. Effect of SKF 38393 (4 mg/kg, i.p.), SCH 23390
(0.25 mg/kg, i.p.), or SCH 23390 Plus SKF 38393 on Equilibrium
Parameters for [125I]Tyr3 Octreotide Binding to Frontoparietal
Cortical Membranes†
Group Bmax Kd
Control 443 6 5 0.60 6 0.02
SKF 38393 601 6 24*** 0.67 6 0.03
SCH 23390 plus SKF 38393 439 6 5 0.63 6 0.04
SCH 23390 487 6 21 0.65 6 0.03
†Binding parameters were calculated from Scatchard plots by linear regres-
sion. Units for Bmax are fmol of SMS 201-995 bound/mg protein and units
for Kd are nM. Data are the mean 6 SEM values of five separate experi-
ments, each performed in duplicate.
***P , 0.001 vs. control.
TABLE II. Effect of Bromocriptine (2 mg/kg, i.p.), Raclopride
(5 mg/kg, i.p.), or Raclopride Plus Bromocriptine on
Equilibrium Parameters for [125I]Tyr3 Octreotide Binding to
Frontoparietal Cortical Membranes†
Group Bmax Kd
Control 441 6 16 0.46 6 0.01
Bromocriptine 610 6 7** 0.49 6 0.01
Raclopride plus bromocriptine 484 6 16 0.42 6 0.02
Raclopride 495 6 25 0.44 6 0.01
†Binding parameters were calculated from Scatchard plots by linear regres-
sion. Units for Bmax are fmol of SMS 201-995 bound/mg protein and units
for Kd are nM. Data are the mean 6 SEM values of five separate experi-
ments, each performed in duplicate.
**P , 0.01 vs. control.
Fig. 3. Effect of increasing concentrations of SMS 201-995 on basal
(open circles) and forskolin-stimulated (solid circles) adenylyl cyclase
activity in rat frontoparietal cortical membranes. The effect of SMS
201-995 was studied in the absence or presence of 1025 M forskolin
and the indicated concentrations of SMS 201-995. Data are expressed
as a percentage of the basal or forskolin-stimulated adenylyl cyclase
activity in the absence of SMS 201-995 (100%). The results are given
as the mean 6 SEM of five separated determination, each performed in
duplicate. Statistical comparison vs. adenylyl cyclase activity in the
absence of SMS 201-995: *P , 0.05.
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995 effect was significantly higher in the SKF 38393-
treated animals than in the bromocriptine-treated animals
(Table III). To test whether the observed changes were
related to modifications in AC expression, we measured
the response of the enzyme to the diterpene FK, which is
assumed to act directly on the catalytic subunit. No sig-
nificant differences were detected in the -fold FK stimu-
lation over basal AC activity between the controls and the
SKF 38393- or bromocriptine-treated group.
The treatment with SKF 38393 did not modify basal
IP3 levels, whereas bromocriptine decreased IP3 accumu-
lation in frontoparietal cortical slices (Fig. 4). SMS 201-
995 significantly increased IP3 accumulation in frontopa-
rietal cortical slices from control, SKF 38393- and
bromocriptine-treated rats (Fig. 4).
DISCUSSION
SKF 38393 and Bromocriptine Increased the
Number of SRIF Receptors
The data reported here suggest that D1- and D2-
receptors are involved in the increase of functional SRIF
receptors in the rat frontoparietal cortex. This was mani-
fested by an increase in the ability of SMS 201-995 to
inhibit FK-stimulated AC activity in the rats treated with
SKF 38393 or bromocriptine. The fact that SKF 38393
and bromocriptine increase the functional activity of SRIF
receptors seems to be a result of activation of D1 and D2
receptors, respectively, in that the effect of SKF 38393 on
SRIF binding was effectively antagonized by the D1-
specific antagonist SCH 23390, whereas the effect of bro-
mocriptine was abolished by the D2-specific antagonist
raclopride. Furthermore, the in vitro addition of the D1 or
D2 DA agonist, SKF 38393 or bromocriptine, respec-
tively, to frontoparietal cortical membranes from un-
treated rats did not affect the SRIF binding parameters.
The present result is in agreement with the result that the
blockage of dopaminergic transmission with haloperidol (3
days) did not affect the number of SRIF receptors in rat
brain (Pe´rez-Oso et al., 1989). The mechanism by which
dopaminergic stimulation increases [125I]Tyr3 octreotide
binding in the frontoparietal cortex is not clear. It has been
demonstrated that sulpiride increases dopaminergic neu-
rotransmision (Elliot et al., 1977). Our research group has
demonstrated that sulpiride significantly decreased the
SRIF-like immunoreactivity levels in the frontoparietal
cortex (Rodrı´guez-Sa´nchez et al., 1994). Therefore, the
decrease in the SRIF-like immunoreactivity content could
explain the increase in Bmax observed. On the other
hand, it is unknown whether this increase in Bmax is
secondary to that of the dopaminergic agonists on other
neurotransmitter systems.
Effects of SKF 38393 and Bromocriptine
on AC Activity
Stimulation of D1 receptors activates AC, whereas
D2 receptor stimulation either inhibits or does not stim-
TABLE III. Effect of SMS 201-995 (1025 M) and Forskolin (1025 M) on Brain Adenylyl Cyclase (AC) Activity in Frontoparietal
Cortical Membranes From Control Rats and Rats Treated With SKF 38393 (4 mg/kg, i.p.) or Bromocriptine (2 mg/kg, i.p.) 3 hr
After Its Administration†
AC activity (pmol of cAMP/min/mg protein)
Control SKF 38393 Control Bromocriptine
Basal activity 152 6 13 205 6 18* 160 6 10 116 6 14*
1 1025 M SMS 201-995 117 6 10 135 6 12 128 6 11 79 6 7*
1 1025 M FK activity 471 6 29 656 6 25** 464 6 24 384 6 18*
Percentage SMS 201-995 inhibition of basal 23 6 3 34 6 3* 20 6 3 32 6 4*
-Fold FK stimulation over basal 3.1 6 0.3 3.2 6 0.4 2.9 6 0.2 3.0 6 0.3
1 1025 M FK 1 1025 M SMS 201-995 353 6 27 419 6 31 357 6 18 230 6 12***
Percentage SMS 201-995 inhibition of FK stimulation 25 6 3 36 6 3* 23 6 3 34 6 3*
†Data are the mean 6 SEM of five separate experiments, each performed in duplicate.
*P , 0.5 vs. control.
**P , 0.01 vs. control.
***P , 0.001 vs. control.
Fig. 4. Comparison of the ability of the somatostatin analogue SMS
201-995 to accumulate IP3 in frontoparietal cortical slices of control,
SKF 38393 (4 mg/kg, i.p.)-treated, and bromocriptine (2 mg/kg,
i.p.)-treated rats. Frontoparietal cortical slices were incubated for 15 sec
at 37°C with 1027 M of SMS 201-995. Values are expressed as the
mean 6 SEM of five separate experiments. Statistical comparison vs.
basal: *P , 0.05; ***P , 0.001. Statistical comparison between basals:
double diamonds, P , 0.01.
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ulate the activity of this enzyme (Kebabian et al., 1984;
Battaglia et al., 1985; Onali et al., 1985; Weiss et al.,
1985). Therefore, our results seem to be in agreement
with the above-mentioned studies. The -fold FK stimu-
lation of AC activity over basal activity was similar in
frontoparietal cortical membranes of control and SKF
38393- or bromocriptine-treated rats, indicating that the
AC catalytic subunit was intact.
Basal and FK-stimulated AC activity was inhibited
by SMS 201-995 in all experimental groups analyzed,
which is in agreement with other authors (Markstein et al.,
1989). A concentration of 1025 M of SMS 201-995 was
required to produce this inhibition. A concentration of
1024 M of SRIF was used by other authors in their studies
on the effect of SRIF on AC activity in rat and human
brain (Schettini, 1991). The high affinity of the SRIF
receptors is incompatible with the SRIF concentration
required to reduce AC activity. In view of the different
response of neuronal and glial cells to SRIF-mediated
inhibition of AC (Chneiweiss et al., 1985a,b; Cola´s et al.,
1992), it is possible that the cell heterogeneity of the
present preparations is responsible for the high SMS 201-
995 concentration necessary to achieve AC inhibition. In
addition, the synaptic SRIF concentration is, so far, un-
known. SMS 201-995-mediated inhibition of basal and
FK-stimulated AC activity was greater in rats treated with
SKF 38393 or bromocriptine than in the control animals.
This increased AC sensitivity to SMS 201-995 induced by
both dopaminergic agonists may be a consequence of the
rise in the number of SRIF receptor observed.
Effects of SKF 38393 and Bromocriptine on IP3
Our results showing that D1-like DA receptor stim-
ulation had no effect on IP3 formation, whereas stimula-
tion of D2-like DA receptors decreased the IP3 formation,
are in agreement with previous studies (Pizzi et al., 1988).
However, there are many contradictory reports in the
literature regarding the effects of D1 DA receptors on
inositol phosphate metabolism. Studies in anterior pitu-
itary cells also suggest that D2 receptor stimulation indi-
rectly suppresses inositol phospholipid hydrolysis (Sim-
monds and Strange, 1985; Journot et al., 1987). However,
Kelly et al. (1988) were unable to observe activation or
inhibition of striatal phosphoinositide metabolism with
either DA or selective D1 and D2 DA receptor agonists.
The discrepancy between our findings and the earlier
reports possibly stems from differences in the drug dose
used and the time points at which the observations were
made. SMS 201-995 significantly increased IP3 accumu-
lation in frontoparietal cortical slices of control rats in
agreement with other studies (Lachowicz et al., 1994;
Mun˜oz-Acedo et al., 1995). The SMS 201-995 concen-
tration eliciting IP3 accumulation was about two orders of
magnitude higher than the corresponding binding. This
apparent discrepancy can be explained by the different
experimental conditions used in each type of experiment.
Our binding studies were obtained at equilibrium after an
incubation of 90 min at 25°C. In contrast, IP3 accumula-
tion is a transient process that must be measured 15 sec
after exposing brain slices to SRIF. Therefore, this very
short period may not be sufficient to reach binding equi-
librium.
The dopamine agonists SKF 38393 and bromocrip-
tine enhance the ability of SMS 201-995 to inhibit basal
and FK-stimulated cAMP accumulation. However, no
differences in SMS 201-995-stimulated phosphoinositides
turnover were detected. Previous studies have demon-
strated uncoupling of receptors from G proteins. In this
regard, Ungar et al. (1993) have demonstrated that estro-
gen uncouples b-adrenergic receptor from the G protein.
Therefore, the differences found between the SMS 201-
995-induced inhibition of cAMP accumulation and the
SMS 201-995-induced stimulation of IP3 accumulation
could be due to an uncoupling of the receptor from Gq
proteins and/or PLC.
The dopaminergic input to the frontal cortex has an
important role in motor and cognitive functions (Gaspar et
al., 1995). These effects are mediated by both D1 and D2
DA receptors (Civelli et al., 1993). In caudate putamen,
nucleus accumbens, olfactory tubercle, substantia nigra,
entopeduncular nucleus, zona incerta, and region of the
ventral internal capsule, D1 receptor subtype was found at
greater density than D2 receptor subtypes. In the olfactory
nerve layer, a higher density of D2 receptor sybtypes was
found in comparison to D1 receptor subtype. In the
ventral tegmental area, the presence of D2 receptor sub-
type was not detected (Boyson et al., 1986). Moderate
densities of mRNA D1 receptor sites are seen in deep
layers of the frontal and parietal cortices, with light diffuse
labeling observed in more superficial layers (Mansour et
al., 1990). Dense levels of D2 receptor mRNA are found
in the layer I and in layers II and III of the frontal and
parietal cortices. However, the deeper layers (V and VI) of
frontal and parietal cortices show moderate to low levels of
D2 receptor mRNA (Mansour et al., 1990). D1 and D2
receptors have been described in different populations of
efferent pyramidal neurons in the rat frontal cortex (Man-
sour et al., 1990; Mansour and Watson, 1995). The ex-
pression of D1 and D2 receptor genes is specific for
different categories of pyramidal neurons (Gaspar et al.,
1995). Recently, the presence of SSTR1, SSTR2,
SSTR3, and SSTR5 receptors in deep layers of frontal and
parietal cortex has been demonstrated (Bruno et al., 1993;
Kong et al., 1994; Pe´rez and Hoyer, 1995). In addition,
the expression of mRNA for SRIF receptor subtypes
SSTR2 and SSTR3 has been found on pyramidal cells in
the cited brain areas (Kong et al., 1994; Pe´rez and Hoyer,
1995). The confirmed presence of DA terminals (Descar-
ries et al., 1987) and SRIF interneurons (Finley et al.,
1981; Johansson et al., 1984) with its specific receptors
(Mansour et al., 1990; Bruno et al., 1993; Kong et al.,
1994; Mansour and Watson, 1995; Pe´rez and Hoyer,
1995) in the deepest layer of the frontal motor areas and
parietal somatosensory areas implies a role in the process-
ing sensoriomotor information (Welker, 1971; Gaspar et
al., 1995). Taken together, the present results support the
notion that the dopaminergic system regulates the binding
96 Izquierdo-Claros et al.
of SRIF to its specific receptors in the rat frontoparietal
cortex.
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